NNC0363-0845 represents a novel insulin formulation aimed at improving glycemic control in patients with type 1 diabetes. The dual administration with insulin detemir allows for comparative analysis of pharmacokinetics and pharmacodynamics, potentially positioning NNC0363-0845 as a competitive alternative in the insulin market. Given the increasing prevalence of diabetes globally, successful outcomes could enhance Novo Nordisk's portfolio and market share in the diabetes care sector. The study's completion suggests readiness for further development stages, with implications for investor confidence and potential partnerships in diabetes management.